An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Trial Parameters
Brief Summary
The purpose of this study is to determine whether AcNK-Sup003 cell injection is safe and effective in the treatment of elapsed or refractory B-cell non-Hodgkin's lymphoma.
Eligibility Criteria
Inclusion Criteria: 1. Signed an informed consent form in writing and is able to comply with the visits and related procedures specified in the protocol. 2. Age ≥18 years old, with an expected survival of more than 3 months. 3. Confirmed by pathology to have CD20+ relapsed or refractory B-cell non-Hodgkin's lymphoma (according to the WHO 2016 lymphoma classification standards), including but not limited to diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and grade 3b follicular lymphoma. 4. Relapsed or refractory disease, defined by one or more of the following: * Relapse, non-response, or progression after hematopoietic stem cell transplantation. * Disease stabilization but with a duration of ≤6 months after at least two cycles of second-line therapy (must have received CD20-targeted drugs \[excluding CD20-negative tumors\] and anthracycline drugs). * Disease progression or relapse after second-line therapy (must have received CD20-targeted drugs \[excluding CD20-negative tu